ANTARES PHARMA INC

ANTARES PHARMA INC

Previous company name
MEDI JECT CORP
Name change date
6/5/1996
Company Overview
Antares Pharma, Inc. (Antares) is a US-based, specialized pharmaceutical product development and pipeline company with drug delivery platforms, including Advanced Transdermal Delivery (ATD) gels, fast-melt oral (Easy Tec) tablets, disposable mini-needle injection systems (Vibex), and reusable needle-free injection systems (VISION and Valeo). The company was created in 2001 when Medi-Ject Corporation, a medical device company, merged with Permatec Holding AG, a developer of transdermal delivery systems.
The Antares Pharma lead ATD gel product is Anturol oxybutynin for the treatment of overactive bladder (OAB). Anturol is the anti-cholinergic oxybutynin delivered by the ATD gel that is used to achieve therapeutic blood levels of the active compound that can be sustained over 24 hours after a single, daily application. The company is committed to developing and commercializing novel therapeutic products utilizing its advanced drug delivery systems.
Antares Pharma operates in three locations: Ewing, New Jersey (corporate offices); Minneapolis, Minnesota (device division); and Basel, Switzerland (GMP – Good Manufacturing Practice – approved pharmaceutical facilities). The company’s shares are traded on the American Stock Exchange under the ticker symbol .
Business Summary
Antares Pharma, Inc. (Antares) is a pharmaceutical company that focuses on self-injection pharmaceutical products and technologies and gel-based products. The Company’s subcutaneous injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, Antares has a multi-product deal with Teva Pharmaceutical Industries, Ltd. (Teva) that includes Tev-Tropin human growth hormone and has partnerships with Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR) that include their human growth hormone (hGH) products. In the gel-based area, its lead product candidate, Anturol, an oxybutynin Advanced Transdermal Delivery (ATD) gel for the treatment of overactive bladder (OAB), was under evaluation in a Phase III trial as of December 31, 2009.
Description and history
Antares Pharma, Inc. (Antares) is a pharmaceutical company that focuses on self-injection pharmaceutical products and technologies and gel-based products. The Company’s subcutaneous injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, Antares has a multi-product deal with Teva Pharmaceutical Industries, Ltd. (Teva) that includes Tev-Tropin human growth hormone and has partnerships with Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR) that include their human growth hormone (hGH) products. In the gel-based area, its lead product candidate, Anturol, an oxybutynin Advanced Transdermal Delivery (ATD) gel for the treatment of overactive bladder (OAB), was under evaluation in a Phase III trial as of December 31, 2009. Antares also has a partnership with BioSante Pharmaceuticals, Inc. (BioSante) that includes LibiGel (transdermal testosterone gel) in Phase III clinical development for the treatment of female sexual dysfunction (FSD), and Elestrin (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the United States.

Pressure Assisted Injection Devices

The Company’s injection device platform features three products: reusable needle-free injectors, disposable pressure assisted auto injectors and disposable pen injectors. Reusable needle-free injectors deliver medication doses through pressurized liquid penetration of the skin without a needle. Its needle-free injector product is a reusable, variable-dose, facilitating self-injection with a disposable syringe. The injector employs a disposable plastic needle-free syringe, which offers liquid medication delivery through an opening that is approximately half the diameter of a 30-gauge needle. The Company has sold its needle-free injection system for use in more than 30 countries to deliver either hGH or insulin. The product is marketed by the Company’s partners for use with hGH as Tjet, by Teva in the United States.; Zomajet 2 Vision and Zomajet Vision X, by Ferring in Europe and Asia, and Twin-Jector EZ II, by JCR in Japan, and is sold as the Medi-Jector VISION over-the-counter (OTC) or by prescription in the United States for use by patients for insulin. The Company refers to its reusable needle-free injector as the Vision and/or Tjet.

Disposable pressure assisted auto injectors employ the technology developed for its needle-free devices, a controlled pressure delivery of drugs into the body utilizing a spring power source. This system, the Vibex, is designed to provide subcutaneous injections. Disposable pen injectors are needle-based devices designed to deliver multiple injections from multi-dose drug cartridges. The devices contain mechanisms that specify the dose to be delivered by defining the amount of movement by the stopper in the cartridge with each device actuation.

Transdermal Gel System

The Company’s transdermal system consists of a formulation in semisolid dosage forms (gels). Its gels are hydro-alcoholic and contain a combination of permeation enhancers to enable drug absorption, through the skin following application, which is typically to the arms, shoulders or abdomen. The Company’s transdermal gel system provides the option of delivering both systemically (penetrating into and through the subcutaneous tissues and then into the circulatory system), as well as locally (topically for skin and soft tissue injury, infection and local inflammation). Antares gel system is known as ATD gels. The Company’s ATD gel products include Anturol, Elestrin, LibiGel, Nestorone and Ropinirole.

The Company competes with Watson Pharmaceuticals, Solvay, Acrux, NexMed, Inc., Auxillium, Inc., Novavax, Inc., Ypsomed AG, SHL Group AB, OwenMumford Ltd., West Pharmaceuticals, Becton Dickinson, Haselmeir GmbH, Elcam Medical and Vetter Pharma, Bioject Medical Technologies Inc. and The Medical House PLC.

Created when Medi-Ject Corporation, a medical device company, merged with Permatec Holding AG, a developer of transdermal delivery systems

Business Line
Specialized pharmaceutical product development and pipeline company with drug delivery platforms, including Advanced Transdermal Delivery (ATD) gels, fast-melt oral (Easy Tec) tablets, disposable mini-needle injection systems (Vibex), and reusable needle-free injection systems (VISION and Valeo)
Subsidiary
ANTARES PHARMA AG
Advisor
KPMG LLP
IPO date
3/8/1999
US SIC Code
3841
Company Address
Suite 290
250, Phillips Boulevard
City province or state postal code
08618, EWING, NJ
Phone: +1 609 359 3020
Fax:
Country address: UNITED STATES OF AMERICA
Website url: www.antarespharma.com